Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
REDWOOD CITY, Calif., Nov. 04, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective November 4, 2016, the compensation committee of the company’s board of directors granted 7 new employees options to purchase an aggregate of 83,000 shares of the company’s common stock with a per share exercise price of $28.15, the closing trading price on the grant date. In addition, 75,000 shares of stock were granted to a Vice President, Marketing new hire and 45,000 shares of stock were granted to a Vice President, Product Development new hire under the same terms. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT: Patrick O’Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 649-3527
